Construction of stable packaging cell lines for clinical lentiviral vector production

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Sanber, Khaled S ^a,b   Knight, Sean B ^a   Stephen, Sam L ^a   Bailey, Ranbir ^a   Escors, David ^a   Minshull, Jeremy ^c   Santilli, Giorgia ^a   Thrasher, Adrian J ^a   Collins, Mary K ^a,b   Takeuchi, Yasuhiro ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c DNA20 Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PR160 GAG-POL PRECURSOR PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN PRECURSOR; REV PROTEIN; REV PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS-1; VIRUS ENVELOPE PROTEIN;

GENE EXPRESSION; GENE VECTOR; GENETICS; HEK293 CELL LINE; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; METABOLISM; RETROVIRIDAE; VIRUS ASSEMBLY;

GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION; GENETIC VECTORS; HEK293 CELLS; HIV-1; HOMOLOGOUS RECOMBINATION; HUMANS; LENTIVIRUS; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN PRECURSORS; RETROVIRIDAE; REV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL ENVELOPE PROTEINS; VIRUS ASSEMBLY;

EID: 84924546283     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09021     Document Type: Article

References (48)

1. Sakuma, T., Barry, M. A. & Ikeda, Y. Lentiviral vectors: basic to translational. Biochem J 443, 603-618, doi:10.1042/bj20120146 (2012).
2. Naldini, L. Ex vivo gene transfer and correction for cell-based therapies. Nature reviews. Genetics 12, 301-315, doi:10.1038/nrg2985 (2011).
3. Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nature reviews. Genetics 12, 316-328, doi:10.1038/nrg2971 (2011).
4. Kochenderfer, J. N. & Rosenberg, S. A. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nature reviews. Clinical oncology 10, 267-276, doi:10.1038/nrclinonc.2013.46 (2013).
5. Kaplan, A. H. & Swanstrom, R. Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments. Proceedings of the National Academy of Sciences of the United States of America 88, 4528-4532 (1991).
6. Nie, Z. et al. HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation. Cell death and differentiation 9, 1172-1184, doi:10.1038/sj.cdd.4401094 (2002).
7. Hoffmann, M. et al. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity. The Journal of general virology 91, 2782-2793, doi:10.1099/vir.0.023978-0 (2010).
8. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322, doi:10.1038/nature09328 (2010).
9. Cartier, N. et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823, doi:10.1126/science.1171242 (2009).
10. Biffi, A. et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science, doi:10.1126/science.1233158 (2013).
11. Aiuti, A. et al. Lentiviral Hematopoietic Stem Cell Gene Therapy in Patients with Wiskott-Aldrich Syndrome. Science, doi:10.1126/science.1233151 (2013).
12. Tebas, P. et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121, 1524-1533, doi:10.1182/blood-2012-07-447250 (2013).
13. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science translational medicine 3, 95ra73, doi:10.1126/scitranslmed.3002842 (2011).
14. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. The New England journal of medicine 365, 725-733, doi:10.1056/NEJMoa1103849 (2011).
15. Pichlmair, A. et al. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J Virol 81, 539-547, doi:10.1128/jvi.01818-06 (2007).
16. Throm, R. E. et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113, 5104-5110, doi:10.1182/blood-2008-11-191049 (2009).
17. Greene, M. R. et al. Transduction of human CD34+ repopulating cells with a self-inactivating lentiviral vector for SCID-X1 produced at clinical scale by a stable cell line. Human gene therapy methods 23, 297-308, doi:10.1089/hgtb.2012.150 (2012).
18. Stewart, H. J., Leroux-Carlucci, M. A., Sion, C. J., Mitrophanous, K. A. & Radcliffe, P. A. Development of inducible EIAV-based lentiviral vector packaging and producer cell lines. Gene Ther 16, 805-814, doi:10.1038/gt.2009.20 (2009).
19. Stewart, H. J. et al. A stable producer cell line for the manufacture of a lentiviral vector for gene therapy of Parkinson's disease. Hum Gene Ther 22, 357-369, doi:10.1089/hum.2010.142 (2011).
20. Ni, Y. et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 7, 818-834, doi:10.1002/jgm.726 (2005).
21. Broussau, S. et al. Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16, 500-507, doi:10.1038/sj.mt.6300383 (2008).
22. Farson, D. et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 12, 981-997, doi:10.1089/104303401750195935 (2001).
23. Ikeda, Y. et al. Continuous high-titer HIV-1 vector production. Nat Biotechnol 21, 569-572, doi:10.1038/nbt815 (2003).
24. Relander, T. et al. Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells. Mol Ther 11, 452-459, doi:10.1016/j.ymthe.2004.10.014 (2005).
25. Sandrin, V. et al. Lentiviral vectors pseudotyped with amodified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100, 823-832, doi:10.1182/blood-2001-11-0042 (2002).
26. Brenner, S. et al. Concentrated RD114-pseudotyped MFGS-gp91phox vector achieves high levels of functional correction of the chronic granulomatous disease oxidase defect in NOD/SCID/beta -microglobulin-/- repopulating mobilized human peripheral blood CD341 cells. Blood 102, 2789-2797, doi:10.1182/blood-2002-05-1482 (2003).
27. Stornaiuolo, A. et al. RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. Human gene therapy methods, doi:10.1089/hgtb.2012.190 (2013).
28. Stacey, G. N. & Merten, O. W. Host cells and cell banking. Methods in molecular biology (Clifton, N. J.) 737, 45-88, doi:10.1007/978-1-61779-095-9-3 (2011).
29. Araki, K., Araki, M. & Yamamura, K. Targeted integration of DNA using mutant lox sites in embryonic stem cells. Nucleic Acids Res 25, 868-872 (1997).
30. Turan, S. & Bode, J. Site-specific recombinases: from tag-and-target- to tag-and-exchange-based genomic modifications. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 25, 4088-4107, doi:10.1096/fj.11-186940 (2011).
31. Ikeda, Y., Ylinen, L. M., Kahar-Bador, M. & Towers, G. J. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 78, 11816-11822 (2004).
32. Chatterji, U. et al. Naturally occurring capsid substitutions render HIV-1 cyclophilin Aindependent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells. J Biol Chem 280, 40293-40300 (2005).
33. Kootstra, N. A., Navis, M., Beugeling, C., van Dort, K. A. & Schuitemaker, H. The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase. Aids 21, 2015-2023, doi:10.1097/QAD.0b013e3282effa87 (2007).
34. Zufferey, R. et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72, 9873-9880 (1998).
35. Montini, E. et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. The Journal of clinical investigation 119, 964-975, doi:10.1172/jci37630 (2009).
36. Modlich, U. et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17, 1919-1928, doi:10.1038/mt.2009.179 (2009).
37. O'Doherty, U., Swiggard, W. J. & Malim, M. H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol 74, 10074-10080 (2000).
38. Strang, B. L., Ikeda, Y., Cosset, F. L., Collins, M. K. & Takeuchi, Y. Characterization of HIV-1 vectors with gammaretrovirus envelope glycoproteins produced from stable packaging cells. Gene Ther 11, 591-598, doi:10.1038/sj.gt.3302189 (2004).
39. Bell, A. J., Jr., Fegen, D., Ward, M. & Bank, A. RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors. Exp Biol Med (Maywood) 235, 1269-1276, doi:10.1258/ebm.2010.010053 (2010).
40. Coffin, J., Hughes, S. & Varmus, H. Retroviruses. 843 (Cold Spring Harbor Laboratory Press, 1997).
41. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650, doi:10.1038/nature00939 (2002).
42. Miller, A. D. & Metzger, M. J. APOBEC3-mediated hypermutation of retroviral vectors produced from some retrovirus packaging cell lines. Gene Ther 18, 528-530, doi:10.1038/gt.2010.177 (2011).
43. Kinomoto, M. et al. All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Res 35, 2955-2964, doi:10.1093/nar/gkm181 (2007).
44. Mukherjee, S. & Thrasher, A. J. Gene therapy for PIDs: Progress, pitfalls and prospects. Gene, doi:10.1016/j.gene.2013.03.098 (2013).
45. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15, 871-875, doi:10.1038/nbt0997-871 (1997).
46. Naldini, L. et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263-267 (1996).
47. Bergsagel, D. J., Finegold, M. J., Butel, J. S., Kupsky, W. J. & Garcea, R. L. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. The New England journal of medicine 326, 988-993, doi:10.1056/nejm199204093261504 (1992).
48. Sastry, L., Xu, Y., Cooper, R., Pollok, K. & Cornetta, K. Evaluation of plasmid DNA removal from lentiviral vectors by benzonase treatment. Hum Gene Ther 15, 221-226, doi:10.1089/104303404772680029 (2004).